This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kosalaraksa, P.
Right arrow Articles by Mitsuya, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kosalaraksa, P.
Right arrow Articles by Mitsuya, H.

 Previous Article  |  Next Article 

Journal of Virology, July 1999, p. 5356-5363, Vol. 73, No. 7
0022-538X/99/$04.00+0

Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay

Pope Kosalaraksa,1 Mark F. Kavlick,1 Victor Maroun,1 Richard Le,1 and Hiroaki Mitsuya1,2,*

Experimental Retrovirology Section, Department of Developmental Therapeutics, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892,1 and Department of Internal Medicine II, Kumamoto University School of Medicine, Kumamoto 860, Japan2

Received 7 October 1998/Accepted 24 March 1999

We examined whether human immunodeficiency virus type 1 (HIV-1) fitness was altered upon the acquisition of a set or subset of five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the pol gene, which confers resistance to multiple dideoxynucleosides (MDR), as well as the zidovudine resistance-associated mutation T215Y, using a competitive HIV-1 replication assay in a setting of an HXB2D genetic background. Target H9 cells were exposed to a 50:50 mixture of paired infectious molecular clones, and HIV-1 in the culture supernatant was transmitted to new cultures every 7 to 10 days. The polymerase-encoding region of the virus was sequenced at various time points, and the relative proportion of the two viral populations was determined. In the absence of drugs, the comparative order for replicative fitness was HIV-162/75/77/116/151 > HIV-177/116/151 > HIV-1151 > wild-type HIV-1 (HIV-1wt) > HIV-175/77/116/151 > HIV-1151/215 > HIV-1215. In the presence of zidovudine or didanosine, the order was HIV-162/75/77/116/151 > HIV-177/116/151 > HIV-175/77/116/151 > HIV-1151 > HIV-1215. HIV-1215S(TCC), a putative intermediate infectious clone for HIV-1215, replicated comparably to HIV-1wt, while two putative intermediates for HIV-1151 [HIV-1151L(CTG) and HIV-1151K(AAG)] replicated much less efficiently than HIV-1wt and HIV-1151, suggesting that for HIV-1151 to develop, two base substitutions are likely to occur concurrently or within a short interval. These data may illustrate the molecular basis by which HIV-1151 emerges much less frequently than HIV-1215. The present data also demonstrate that several MDR HIV-1 variants are more fit than HIV-1wt in the absence of drugs and that resistance-associated mutations and drug pressure are critical variates for HIV-1 fitness.

* Corresponding author. Mailing address: Experimental Retrovirology Section, Medicine Branch, National Cancer Institute, Bldg. 10, Room 5A11, Bethesda, MD 20892. Phone: (301) 496-9238. Fax: (301) 402-0709. E-mail: hmitsuya{at}helix.nih.gov.

Journal of Virology, July 1999, p. 5356-5363, Vol. 73, No. 7
0022-538X/99/$04.00+0


This article has been cited by other articles:

  • Matamoros, T., Nevot, M., Martinez, M. A., Menendez-Arias, L. (2009). Thymidine Analogue Resistance Suppression by V75I of HIV-1 Reverse Transcriptase: EFFECTS OF SUBSTITUTING VALINE 75 ON STAVUDINE EXCISION AND DISCRIMINATION. J. Biol. Chem. 284: 32792-32802 [Abstract] [Full Text]  
  • Ambrose, Z., Herman, B. D., Sheen, C.-W., Zelina, S., Moore, K. L., Tachedjian, G., Nissley, D. V., Sluis-Cremer, N. (2009). The Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation I132M Confers Hypersensitivity to Nucleoside Analogs. J. Virol. 83: 3826-3833 [Abstract] [Full Text]  
  • Aoki, M., Venzon, D. J., Koh, Y., Aoki-Ogata, H., Miyakawa, T., Yoshimura, K., Maeda, K., Mitsuya, H. (2009). Non-Cleavage Site Gag Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay Development of Resistance to Other Protease Inhibitors. J. Virol. 83: 3059-3068 [Abstract] [Full Text]  
  • Basavapathruni, A., Anderson, K. S. (2007). Reverse transcription of the HIV-1 pandemic. FASEB J. 21: 3795-3808 [Abstract] [Full Text]  
  • Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  
  • Cong, M.-e., Heneine, W., Garcia-Lerma, J. G. (2007). The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions. J. Virol. 81: 3037-3041 [Abstract] [Full Text]  
  • Gatanaga, H., Das, D., Suzuki, Y., Yeh, D. D., Hussain, K. A., Ghosh, A. K., Mitsuya, H. (2006). Altered HIV-1 Gag Protein Interactions with Cyclophilin A (CypA) on the Acquisition of H219Q and H219P Substitutions in the CypA Binding Loop. J. Biol. Chem. 281: 1241-1250 [Abstract] [Full Text]  
  • Nitanda, T., Wang, X., Kumamoto, H., Haraguchi, K., Tanaka, H., Cheng, Y.-C., Baba, M. (2005). Anti-Human Immunodeficiency Virus Type 1 Activity and Resistance Profile of 2',3'-Didehydro-3'-Deoxy-4'-Ethynylthymidine In Vitro. Antimicrob. Agents Chemother. 49: 3355-3360 [Abstract] [Full Text]  
  • Nameki, D., Kodama, E., Ikeuchi, M., Mabuchi, N., Otaka, A., Tamamura, H., Ohno, M., Fujii, N., Matsuoka, M. (2005). Mutations Conferring Resistance to Human Immunodeficiency Virus Type 1 Fusion Inhibitors Are Restricted by gp41 and Rev-Responsive Element Functions. J. Virol. 79: 764-770 [Abstract] [Full Text]  
  • Bouchonnet, F., Dam, E., Mammano, F., de Soultrait, V., Hennere, G., Benech, H., Clavel, F., Hance, A. J. (2005). Quantification of the Effects on Viral DNA Synthesis of Reverse Transcriptase Mutations Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Analogues. J. Virol. 79: 812-822 [Abstract] [Full Text]  
  • Paolucci, S., Baldanti, F., Maga, G., Cancio, R., Zazzi, M., Zavattoni, M., Chiesa, A., Spadari, S., Gerna, G. (2004). Gln145Met/Leu Changes in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nucleoside and Nonnucleoside Analogs and Impair Virus Replication. Antimicrob. Agents Chemother. 48: 4611-4617 [Abstract] [Full Text]  
  • Tamiya, S., Mardy, S., Kavlick, M. F., Yoshimura, K., Mistuya, H. (2004). Amino Acid Insertions near Gag Cleavage Sites Restore the Otherwise Compromised Replication of Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors. J. Virol. 78: 12030-12040 [Abstract] [Full Text]  
  • Smith, R. A., Anderson, D. J., Preston, B. D. (2004). Purifying Selection Masks the Mutational Flexibility of HIV-1 Reverse Transcriptase. J. Biol. Chem. 279: 26726-26734 [Abstract] [Full Text]  
  • Lu, J., Sista, P., Giguel, F., Greenberg, M., Kuritzkes, D. R. (2004). Relative Replicative Fitness of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide (T-20). J. Virol. 78: 4628-4637 [Abstract] [Full Text]  
  • Clavel, F., Hance, A. J. (2004). HIV Drug Resistance. NEJM 350: 1023-1035 [Full Text]  
  • Collins, J. A., Thompson, M. G., Paintsil, E., Ricketts, M., Gedzior, J., Alexander, L. (2004). Competitive Fitness of Nevirapine-Resistant Human Immunodeficiency Virus Type 1 Mutants. J. Virol. 78: 603-611 [Abstract] [Full Text]  
  • Weber, J., Rangel, H. R., Chakraborty, B., Tadele, M., Martinez, M. A., Martinez-Picado, J., Marotta, M. L., Mirza, M., Ruiz, L., Clotet, B., Wrin, T., Petropoulos, C. J., Quinones-Mateu, M. E. (2003). A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J. Gen. Virol. 84: 2217-2228 [Abstract] [Full Text]  
  • Nurpeisov, V., Hurwitz, S. J., Sharma, P. L. (2003). Fluorescent Dye Terminator Sequencing Methods for Quantitative Determination of Replication Fitness of Human Immunodeficiency Virus Type 1 Containing the Codon 74 and 184 Mutations in Reverse Transcriptase. J. Clin. Microbiol. 41: 3306-3311 [Abstract] [Full Text]  
  • Deval, J., Selmi, B., Boretto, J., Egloff, M. P., Guerreiro, C., Sarfati, S., Canard, B. (2002). The Molecular Mechanism of Multidrug Resistance by the Q151M Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Its Suppression Using alpha -Boranophosphate Nucleotide Analogues. J. Biol. Chem. 277: 42097-42104 [Abstract] [Full Text]  
  • Ray, A. S., Basavapathruni, A., Anderson, K. S. (2002). Mechanistic Studies to Understand the Progressive Development of Resistance in Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Abacavir. J. Biol. Chem. 277: 40479-40490 [Abstract] [Full Text]  
  • Quinones-Mateu, M. E., Tadele, M., Parera, M., Mas, A., Weber, J., Rangel, H. R., Chakraborty, B., Clotet, B., Domingo, E., Menendez-Arias, L., Martinez, M. A. (2002). Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation. J. Virol. 76: 10546-10552 [Abstract] [Full Text]  
  • Kijak, G. H., Simon, V., Balfe, P., Vanderhoeven, J., Pampuro, S. E., Zala, C., Ochoa, C., Cahn, P., Markowitz, M., Salomon, H. (2002). Origin of Human Immunodeficiency Virus Type 1 Quasispecies Emerging after Antiretroviral Treatment Interruption in Patients with Therapeutic Failure. J. Virol. 76: 7000-7009 [Abstract] [Full Text]  
  • Gatanaga, H., Suzuki, Y., Tsang, H., Yoshimura, K., Kavlick, M. F., Nagashima, K., Gorelick, R. J., Mardy, S., Tang, C., Summers, M. F., Mitsuya, H. (2002). Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease Inhibitors. J. Biol. Chem. 277: 5952-5961 [Abstract] [Full Text]  
  • Iglesias-Ussel, M. D., Casado, C., Yuste, E., Olivares, I., Lopez-Galindez, C. (2002). In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J. Gen. Virol. 83: 93-101 [Abstract] [Full Text]  
  • Kim, E.-Y., Winters, M. A., Kagan, R. M., Merigan, T. C. (2001). Functional Correlates of Insertion Mutations in the Protease Gene of Human Immunodeficiency Virus Type 1 Isolates from Patients. J. Virol. 75: 11227-11233 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G., Nidtha, S., Blumoff, K., Weinstock, H., Heneine, W. (2001). Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 10.1073/pnas.241300698v1 [Abstract] [Full Text]  
  • Kanamoto, T., Kashiwada, Y., Kanbara, K., Gotoh, K., Yoshimori, M., Goto, T., Sano, K., Nakashima, H. (2001). Anti-Human Immunodeficiency Virus Activity of YK-FH312 (a Betulinic Acid Derivative), a Novel Compound Blocking Viral Maturation. Antimicrob. Agents Chemother. 45: 1225-1230 [Abstract] [Full Text]  
  • Bleiber, G., Munoz, M., Ciuffi, A., Meylan, P., Telenti, A. (2001). Individual Contributions of Mutant Protease and Reverse Transcriptase to Viral Infectivity, Replication, and Protein Maturation of Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1. J. Virol. 75: 3291-3300 [Abstract] [Full Text]  
  • Imamichi, T., Berg, S. C., Imamichi, H., Lopez, J. C., Metcalf, J. A., Falloon, J., Lane, H. C. (2000). Relative Replication Fitness of a High-Level 3'-Azido-3'-Deoxythymidine-Resistant Variant of Human Immunodeficiency Virus Type 1 Possessing an Amino Acid Deletion at Codon 67 and a Novel Substitution (Thrright-arrowGly) at Codon 69. J. Virol. 74: 10958-10964 [Abstract] [Full Text]  
  • García-Lerma, J. G., Gerrish, P. J., Wright, A. C., Qari, S. H., Heneine, W. (2000). Evidence of a Role for the Q151L Mutation and the Viral Background in Development of Multiple Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1. J. Virol. 74: 9339-9346 [Abstract] [Full Text]  
  • Van Vaerenbergh, K., Van Laethem, K., Albert, J., Boucher, C. A. B., Clotet, B., Floridia, M., Gerstoft, J., Hejdeman, B., Nielsen, C., Pannecouque, C., Perrin, L., Pirillo, M. F., Ruiz, L., Schmit, J.-C., Schneider, F., Schoolmeester, A., Schuurman, R., Stellbrink, H. J., Stuyver, L., Van Lunzen, J., Van Remoortel, B., Van Wijngaerden, E., Vella, S., Witvrouw, M., Yerly, S., De Clercq, E., Desmyter, J., Vandamme, A.-M. (2000). Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues. Antimicrob. Agents Chemother. 44: 2109-2117 [Abstract] [Full Text]  
  • Yoshimura, K., Feldman, R., Kodama, E., Kavlick, M. F., Qiu, Y.-L., Zemlicka, J., Mitsuya, H. (1999). In Vitro Induction of Human Immunodeficiency Virus Type 1 Variants Resistant to Phosphoralaninate Prodrugs of Z-Methylenecyclopropane Nucleoside Analogues. Antimicrob. Agents Chemother. 43: 2479-2483 [Abstract] [Full Text]  
  • Shah, F. S., Curr, K. A., Hamburgh, M. E., Parniak, M., Mitsuya, H., Arnez, J. G., Prasad, V. R. (2000). Differential Influence of Nucleoside Analog-resistance Mutations K65R and L74V on the Overall Mutation Rate and Error Specificity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. J. Biol. Chem. 275: 27037-27044 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G., Nidtha, S., Blumoff, K., Weinstock, H., Heneine, W. (2001). From the Cover: Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 98: 13907-13912 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»